Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation

Yoshiko Atsuta, Akihiro Hirakawa, Hideki Nakasone, Saiko Kurosawa, Kumi Oshima, Rika Sakai, Kazuteru Ohashi, Satoshi Takahashi, Takehiko Mori, Yukiyasu Ozawa, Takahiro Fukuda, Heiwa Kanamori, Yasuo Morishima, Koji Kato, Hiromasa Yabe, Hisashi Sakamaki, Shuichi Taniguchi, Takuya Yamashita

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We sought to assess the late mortality risks and causes of death among long-term survivors of allogeneic hematopoietic stem cell transplantation (HCT). The cases of 11,047 relapse-free survivors of a first HCT at least 2 years after HCT were analyzed. Standardized mortality ratios (SMR) were calculated and specific causes of death were compared with those of the Japanese population. Among relapse-free survivors at 2 years, overall survival percentages at 10 and 15 years were 87% and 83%, respectively. The overall risk of mortality was significantly higher compared with that of the general population. The risk of mortality was significantly higher from infection (SMR = 57.0), new hematologic malignancies (SMR = 2.2), other new malignancies (SMR = 3.0), respiratory causes (SMR = 109.3), gastrointestinal causes (SMR = 3.8), liver dysfunction (SMR = 6.1), genitourinary dysfunction (SMR = 17.6), and external or accidental causes (SMR = 2.3). The overall annual mortality rate showed a steep decrease from 2 to 5 years after HCT; however, the decrease rate slowed after 10 years but was still higher than that of the general population at 20 years after HCT. SMRs in the earlier period of 2 to 4 years after HCT and 5 years or longer after HCT were 16.1 and 7.4, respectively. Long-term survivors after allogeneic HCT are at higher risk of mortality from various causes other than the underlying disease that led to HCT. Screening and preventive measures should be given a central role in reducing the morbidity and mortality of HCT recipients on long-term follow-up.

Original languageEnglish
JournalBiology of Blood and Marrow Transplantation
DOIs
Publication statusAccepted/In press - 2016 Feb 18

Fingerprint

Stem Cell Transplantation
Survivors
Cause of Death
Hematopoietic Stem Cell Transplantation
Mortality
Population
Recurrence
Hematologic Neoplasms
Liver Diseases

Keywords

  • Causes of death
  • Late effects
  • Late mortality

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation. / Atsuta, Yoshiko; Hirakawa, Akihiro; Nakasone, Hideki; Kurosawa, Saiko; Oshima, Kumi; Sakai, Rika; Ohashi, Kazuteru; Takahashi, Satoshi; Mori, Takehiko; Ozawa, Yukiyasu; Fukuda, Takahiro; Kanamori, Heiwa; Morishima, Yasuo; Kato, Koji; Yabe, Hiromasa; Sakamaki, Hisashi; Taniguchi, Shuichi; Yamashita, Takuya.

In: Biology of Blood and Marrow Transplantation, 18.02.2016.

Research output: Contribution to journalArticle

Atsuta, Y, Hirakawa, A, Nakasone, H, Kurosawa, S, Oshima, K, Sakai, R, Ohashi, K, Takahashi, S, Mori, T, Ozawa, Y, Fukuda, T, Kanamori, H, Morishima, Y, Kato, K, Yabe, H, Sakamaki, H, Taniguchi, S & Yamashita, T 2016, 'Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2016.05.019
Atsuta, Yoshiko ; Hirakawa, Akihiro ; Nakasone, Hideki ; Kurosawa, Saiko ; Oshima, Kumi ; Sakai, Rika ; Ohashi, Kazuteru ; Takahashi, Satoshi ; Mori, Takehiko ; Ozawa, Yukiyasu ; Fukuda, Takahiro ; Kanamori, Heiwa ; Morishima, Yasuo ; Kato, Koji ; Yabe, Hiromasa ; Sakamaki, Hisashi ; Taniguchi, Shuichi ; Yamashita, Takuya. / Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2016.
@article{0c9bdd5fe0fe4aab88fcda5fb0d05553,
title = "Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation",
abstract = "We sought to assess the late mortality risks and causes of death among long-term survivors of allogeneic hematopoietic stem cell transplantation (HCT). The cases of 11,047 relapse-free survivors of a first HCT at least 2 years after HCT were analyzed. Standardized mortality ratios (SMR) were calculated and specific causes of death were compared with those of the Japanese population. Among relapse-free survivors at 2 years, overall survival percentages at 10 and 15 years were 87{\%} and 83{\%}, respectively. The overall risk of mortality was significantly higher compared with that of the general population. The risk of mortality was significantly higher from infection (SMR = 57.0), new hematologic malignancies (SMR = 2.2), other new malignancies (SMR = 3.0), respiratory causes (SMR = 109.3), gastrointestinal causes (SMR = 3.8), liver dysfunction (SMR = 6.1), genitourinary dysfunction (SMR = 17.6), and external or accidental causes (SMR = 2.3). The overall annual mortality rate showed a steep decrease from 2 to 5 years after HCT; however, the decrease rate slowed after 10 years but was still higher than that of the general population at 20 years after HCT. SMRs in the earlier period of 2 to 4 years after HCT and 5 years or longer after HCT were 16.1 and 7.4, respectively. Long-term survivors after allogeneic HCT are at higher risk of mortality from various causes other than the underlying disease that led to HCT. Screening and preventive measures should be given a central role in reducing the morbidity and mortality of HCT recipients on long-term follow-up.",
keywords = "Causes of death, Late effects, Late mortality",
author = "Yoshiko Atsuta and Akihiro Hirakawa and Hideki Nakasone and Saiko Kurosawa and Kumi Oshima and Rika Sakai and Kazuteru Ohashi and Satoshi Takahashi and Takehiko Mori and Yukiyasu Ozawa and Takahiro Fukuda and Heiwa Kanamori and Yasuo Morishima and Koji Kato and Hiromasa Yabe and Hisashi Sakamaki and Shuichi Taniguchi and Takuya Yamashita",
year = "2016",
month = "2",
day = "18",
doi = "10.1016/j.bbmt.2016.05.019",
language = "English",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation

AU - Atsuta, Yoshiko

AU - Hirakawa, Akihiro

AU - Nakasone, Hideki

AU - Kurosawa, Saiko

AU - Oshima, Kumi

AU - Sakai, Rika

AU - Ohashi, Kazuteru

AU - Takahashi, Satoshi

AU - Mori, Takehiko

AU - Ozawa, Yukiyasu

AU - Fukuda, Takahiro

AU - Kanamori, Heiwa

AU - Morishima, Yasuo

AU - Kato, Koji

AU - Yabe, Hiromasa

AU - Sakamaki, Hisashi

AU - Taniguchi, Shuichi

AU - Yamashita, Takuya

PY - 2016/2/18

Y1 - 2016/2/18

N2 - We sought to assess the late mortality risks and causes of death among long-term survivors of allogeneic hematopoietic stem cell transplantation (HCT). The cases of 11,047 relapse-free survivors of a first HCT at least 2 years after HCT were analyzed. Standardized mortality ratios (SMR) were calculated and specific causes of death were compared with those of the Japanese population. Among relapse-free survivors at 2 years, overall survival percentages at 10 and 15 years were 87% and 83%, respectively. The overall risk of mortality was significantly higher compared with that of the general population. The risk of mortality was significantly higher from infection (SMR = 57.0), new hematologic malignancies (SMR = 2.2), other new malignancies (SMR = 3.0), respiratory causes (SMR = 109.3), gastrointestinal causes (SMR = 3.8), liver dysfunction (SMR = 6.1), genitourinary dysfunction (SMR = 17.6), and external or accidental causes (SMR = 2.3). The overall annual mortality rate showed a steep decrease from 2 to 5 years after HCT; however, the decrease rate slowed after 10 years but was still higher than that of the general population at 20 years after HCT. SMRs in the earlier period of 2 to 4 years after HCT and 5 years or longer after HCT were 16.1 and 7.4, respectively. Long-term survivors after allogeneic HCT are at higher risk of mortality from various causes other than the underlying disease that led to HCT. Screening and preventive measures should be given a central role in reducing the morbidity and mortality of HCT recipients on long-term follow-up.

AB - We sought to assess the late mortality risks and causes of death among long-term survivors of allogeneic hematopoietic stem cell transplantation (HCT). The cases of 11,047 relapse-free survivors of a first HCT at least 2 years after HCT were analyzed. Standardized mortality ratios (SMR) were calculated and specific causes of death were compared with those of the Japanese population. Among relapse-free survivors at 2 years, overall survival percentages at 10 and 15 years were 87% and 83%, respectively. The overall risk of mortality was significantly higher compared with that of the general population. The risk of mortality was significantly higher from infection (SMR = 57.0), new hematologic malignancies (SMR = 2.2), other new malignancies (SMR = 3.0), respiratory causes (SMR = 109.3), gastrointestinal causes (SMR = 3.8), liver dysfunction (SMR = 6.1), genitourinary dysfunction (SMR = 17.6), and external or accidental causes (SMR = 2.3). The overall annual mortality rate showed a steep decrease from 2 to 5 years after HCT; however, the decrease rate slowed after 10 years but was still higher than that of the general population at 20 years after HCT. SMRs in the earlier period of 2 to 4 years after HCT and 5 years or longer after HCT were 16.1 and 7.4, respectively. Long-term survivors after allogeneic HCT are at higher risk of mortality from various causes other than the underlying disease that led to HCT. Screening and preventive measures should be given a central role in reducing the morbidity and mortality of HCT recipients on long-term follow-up.

KW - Causes of death

KW - Late effects

KW - Late mortality

UR - http://www.scopus.com/inward/record.url?scp=84979623023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979623023&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2016.05.019

DO - 10.1016/j.bbmt.2016.05.019

M3 - Article

C2 - 27246369

AN - SCOPUS:84979623023

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -